Publications
5808 Results
- Journal / Conference
- Journal of Urology 173(4):143 (#525)
- Year
- 2005
- Research Committee(s)
- Cancer Control
- Study Number(s)
- SWOG-9217
Prostate specific antigen (PSA) as a predictor of adverse pathological features at prostatectomy in the Prostate Cancer Prevention Trial (PCPT)
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):391s (#4556)
- Year
- 2005
- Research Committee(s)
- Genitourinary
- Study Number(s)
- SWOG-8994 (EST-C-0690) (INT-0086)
Short-and long-term genitourinary symptom status and global quality of life (QOL) from a Southwest Oncology Group (SWOG) trial
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):5s (#507)
- Year
- 2005
- Research Committee(s)
- Breast
- Study Number(s)
- SWOG-9313
Prognostic value of cell cycle regulators p27 and cyclin E: tissue microarray analysis of 1753 women enrolled in SWOG breast cancer trial 9313
- Journal / Conference
- Proc of the ASO, JCO 23(16S):458s (#5013)
- Year
- 2005
- Research Committee(s)
- Gynecologic
- Study Number(s)
- S9701
Relationship between pretreatment CA-125 level and risk of relapse in advanced ovarian cancer (AOC) patients in a complete clinical response (CCR) who received "maintenance therapy"
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):635s (#7059)
- Year
- 2005
- Research Committee(s)
- Lung
- Study Number(s)
- SWOG-9504
Long term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504)
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):818s (#9010)
- Year
- 2005
- Research Committee(s)
- Sarcoma
- Study Number(s)
- S0033
Clinical benefit of Imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial.
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):824s (#9032)
- Year
- 2005
- Research Committee(s)
- Sarcoma
- Study Number(s)
- S0033
Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the phase III intergroup study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST)
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):20s (#567)
- Year
- 2005
- Research Committee(s)
- Breast
- Study Number(s)
- S0102
SWOG S0102: a phase II study of docetaxel (DOC) and vinorelbine (VNR) + filgrastim for HER-2 negative, stage IV breast cancer
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):583s (#6592)
- Year
- 2005
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0108
Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group study S0108
- Journal / Conference
- Proc of the ASCO, JCO 23(16S):628s (#7030)
- Year
- 2005
- Research Committee(s)
- Lung
- Study Number(s)
- S0126